Cohen C.J., Meyers J.L., Davis K.L. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open, 2013, Vol. 3, pp. e003028. URL:http://bmjopen.bmj.com/content/3/8/e003028, doi: 10.1136/bmjopen-2013-003028..
DOI: 10.1136/bmjopen-2013-003028http://bmjopen.bmj.com/content/3/8/e003028,
Cohen C.J., Kubota M., Brachman P.S. Abacavir-Lamivudine Once-Daily HIV Assessment (ALOHA) Study Group. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study. Pharmacotherapy, 2008, Vol. 28 (3), рр. 314–322.
Eron J.J., Yetzer E.S., Ruane P.J., Becker S., Sawyer G.A., Fisher R.L., Tolson J.M., Shaefer M.S. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS, 2000, Vol. 14 (6), рр. 671–681.
Homar F., Lozano V., Martínez-Gómez J., Oyagüez I., Pareja A., Payeras A., Serrano J., Carratalá C., Casado M.A. Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Economics Review, 2012, Vol. 2, рр. 16.
Кашеваров А.Б. О рассмотрении обращения: Письмо ФАС России от 09.06.2015 № АК/28644/15. URI: http://docs.cntd.ru/document/420317526 (14.05.2016) [Электронный текст документа].http://docs.cntd.ru/document/420317526
Sax P.E., Meyers J.L., Mugavero M., Davis K.L. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One, 2012, Vol. 7 (2), рр. e31591. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286454.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286454
Нижегородцев Т.В. О государственных закупках антивирусных препаратов, предназначенных для лечения лиц, инфицированных вирусом иммунодефицита человека (комбинированных и монопрепаратов): разъяснительное письмо ФАС от 24.08.2010. URL: http://fas.gov.ru/http://fas.gov.ru/
documents/documentdetails.html?id=880 (20.12.2016).
De Jesus E., Herrera G., Teofilo E., Gerstoft J., Buendia C.B., Brand J.D., Brothers C.H., Hernandez J., Castillo S.A., Bonny T., Lanier E.R. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis., 2004, Vol. 739 (7), рр. 1038–1046.